Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70040 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Shobha N Bhattachar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Obesity, Overweight, Weight Loss, Anti-Obesity Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Aim
Mazdutide, an agonist of glucagon‐like peptide‐1 and glucagon receptors, significantly reduced weight in early phase trials at doses up to 10 mg. This randomized, double‐blind, placebo‐controlled Phase 1 trial evaluated the safety and efficacy of mazdutide up to 16 mg in adults with overweight or obesity. Materials and Methods Thirty‐two adults with overweight/obesity without diabetes received once‐weekly subcutaneous injections of mazdutide ( n = 24) or placebo ( n = 8) for 20 weeks. Two mazdutide dose escalation regimens (Cohorts 1 and 2, n = 12 each) were used to reach a 16‐mg target dose. Data were analysed using descriptive statistics and mixed model repeated measures to estimate least square means with standard error (SE).
Results
At Week 20, mean percent change from baseline in body weight was −20.0% (SE: 1.9) for Cohort 1 and −21.0% (1.2) for Cohort 2 versus −0.1% (1.5) for placebo ( p < 0.001). Weight loss of ≥15% was achieved by 66.7% of Cohort 1 and 75.0% of Cohort 2. No placebo participants achieved ≥5% weight loss. Mean percent change in waist circumference was −12.0% (SE: 1.7) in Cohort 1 and −17.0% (1.7) in Cohort 2 versus −0.8% (2.1) in placebo ( p < 0.001). Improved fasting metabolic biomarker profiles and reduced appetite were associated with mazdutide treatment. No serious adverse events (AEs) were reported, and the most common AEs were mild or moderate gastrointestinal disorders.
Conclusions
Mazdutide at 16 mg was well tolerated and associated with greater weight loss at higher doses than previously studied and improved metabolic regulation in adults with overweight or obesity. US Clinical Trials Registry: NCT05623839.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, Indiana, USA.
ORCID-Profile: Lai San Tham, Kieren J Mather, Melissa K Thomas
Förderung
- Eli Lilly and Company
Zitieren
APA
Bhattachar, S. N., Tham, L. S., Li, Y., Chua, L., Ng, S. X., Tang, Y., Ibriga, H., Ni, W., Gurbuz, S., Mather, K. J., & Thomas, M. K. (2025). Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70040
Vancouver
Bhattachar SN, Tham LS, Li Y, Chua L, Ng SX, Tang Y, et al. Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70040
BibTeX
@article{Bhattachar2025,
author = {Bhattachar, Shobha N and Tham, Lai San and Li, Yan and Chua, Laiyi and Ng, Shu Xuan and Tang, Yuanyuan and Ibriga, Hilda and Ni, Wei and Gurbuz, Sirel and Mather, Kieren J and Thomas, Melissa K},
title = {Mazdutide reduces body weight in adults with overweight or obesity: A high‐dose Phase 1 trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70040}
}
EUVIMED